MYOS RENS takes its responsibility to the environment and the community very seriously. MYOS RENS is committed to being a good corporate citizen and welcomes suggestions on enhancing our contributions in this regard.
Men and Women (60-75 Years of Age) Who Received Fortetropin® Experienced an Average Increase in Muscle Protein Synthesis Rate of 18% in Randomized, Double Blind, Placebo-Controlled Human Clinical Trial
CEDAR KNOLLS, N.J., July 7, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and [...]
CEDAR KNOLLS, N.J. and MISSISSAUGA, Ontario, June 30, 2020 /PRNewswire/ -- MYOS RENS Technology, Inc. ("MYOS") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, and MedAvail, Inc. ("MedAvail"), a private, in-clinic telemedicine-enabled pharmacy [...]